The modified male mosquito named '513A' will have a gene that ensures its offspring dies before reaching adulthood (in 2-5 days) and thus control breeding of dengue spreading mosquitoes.
This genetically-modified mosquito has been tested in Brazil, where dengue emerged as a big worry during the recently concluded World Cup Football tournament, and the Cayman Islands.
UK-based Oxitec, an Oxford University spin-out which develops technologies for controlling insects, has approached the Indian government for necessary approvals to begin trials for GM mosquitoes here.
"Oxitec is working with GBIT, a privately held Indian company that specialises in developing and commercialising novel technologies in health and agriculture, with a view to introducing this technology for dengue vector control in India," the spokesperson said.
Thousands of dengue cases are reported every year in India.
"In due course, we would like to use the same approach for the main vectors of malaria but this work is at a very early stage," he said.
With regard to regulatory clearances, GBIT has already received nod for contained laboratory-based studies. Besides, permission for larger technology trials has been sought from the Review Committee for Genetic Manipulation (RCGM).
Field based studies would only begin following appraisal and approval by the relevant national bio safety committees, RCGM and Genetic Engineering Approval Committee (GEAC).
RCGM and GEAC come under the Ministry of Environment and Forests.
"We expect a large-scale trial to be the next step; however, the timing is entirely within the hands of the RCGM," the official noted.
These GM male mosquitoes can mate only with females of the same species (dengue spreading), so that it is exclusively targeted to the dengue mosquito with no effect on other insect species.
"Every wild female which mates one of our modified males will have offspring who carry the gene and without the antidote, they won't survive.
"In this way, by repeatedly releasing Oxitec males, we can drastically reduce or even locally eliminate the dengue mosquito population," he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
